Cancers, Vol. 11, Pages 1256: Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma

Conclusion: Predictors to satisfy the RESORCE study inclusion criteria were as follows: preserved liver function at baseline, as reflected by albumin or ALBI score, and small deterioration of liver function early during sorafenib therapy, as reflected by Δalbumin or ΔALBI at week 4. Liver function at baseline and degree of change in liver function during sorafenib treatment need to be stricter for better outcomes of liver function with disease progression.

Source: Cancers - August 26, 2019 Category: Cancer & Oncology Authors: Takada Kurosaki Tsuchiya Komiyama Itakura Takahashi Nakanishi Yasui Tamaki Maeyashiki Kaneko Takaura Higuchi Okada Wang Osawa Sekiguchi Hayakawa Yamashita Enomoto Izumi Tags: Article Source Type: research